Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6254-6264

  Kirby, Karen A ^a,b   Michailidis, Eleftherios ^a,b   Fetterly, Tracy L ^a,b   Steinbach, Musetta A ^a,b   Singh, Kamalendra ^a,b   Marchand, Bruno ^a,b   Leslie, Maxwell D ^a,b   Hagedorn, Ariel N ^a,b   Kodama, Eiichi N ^c   Marquez, Victor E ^d   Hughes, Stephen H ^d   Mitsuya, Hiroaki ^e,f   Parniak, Michael A ^g   Sarafianos, Stefan G ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

^e KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' ETHYNYL 2 FLUORO 2' DEOXYADENOSINE; ADENINE; ADENOSINE DEAMINASE; DEOXYADENOSINE; DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; SUGAR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CONFORMATION; DEAMINATION; DNA STRAND; HUMAN IMMUNODEFICIENCY VIRUS; KINETICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; STEADY STATE;

DEOXYADENOSINES; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84887415871     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01703-13     Document Type: Article

References (71)

1. Parniak MA, Sluis-Cremer N. 2000. Inhibitors of HIV-1 reverse transcriptase. Adv. Pharmacol. 49:67-109.
2. Painter GR, Almond MR, Mao S, Liotta DC. 2004. Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase. Curr. Top. Med. Chem. 4:1035-1044.
3. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. 2006. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-U. S. A. panel. Top. HIV Med. 14:827-843.
4. De Clercq E. 2007. Anti-HIV drugs. Verh. K. Acad. Geneeskd. Belg. 69:81-104.
5. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, Arnold E. 2009. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 385:693-713.
6. Schinazi RF, Bassit L, Gavegnano C. 2010. HCV drug discovery aimed at viral eradication. J. Viral Hepat. 17:77-90.
7. Wauchope OR, Tomney MJ, Pepper JL, Korba BE, Seley-Radtke KL. 2010. Tricyclic 2'-C-modified nucleosides as potential anti-HCV therapeutics. Org. Lett. 12:4466-4469.
8. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2', 3'-dideoxy-3'-thiacytidine and related analogues. Proc. Natl. Acad. Sci. U. S. A. 88:8495-8499.
9. Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim SO, Folk WR, Sarafianos SG. 2012. Antiviral therapies: focus on hepatitis B reverse transcriptase. Int. J. Biochem. Cell Biol. 44:1060-1071.
10. Wauchope OR, Johnson C, Krishnamoorthy P, Andrei G, Snoeck R, Balzarini J, Seley-Radtke KL. 2012. Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues. Bioorg. Med. Chem. 20:3009-3015.
11. Gallois-Montbrun S, Schneider B, Chen Y, Giacomoni-Fernandes V, Mulard L, Morera S, Janin J, Deville-Bonne D, Veron M. 2002. Improving nucleoside diphosphate kinase for antiviral nucleotide analogs activation. J. Biol. Chem. 277:39953-39959.
12. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. 1998. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12:1735-1744.
13. Kakuda TN. 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22: 685-708.
14. Lewis W, Day BJ, Copeland WC. 2003. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2:812-822.
15. Sluis-Cremer N, Arion D, Parniak MA. 2000. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell. Mol. Life Sci. 57:1408-1422.
16. Menendez-Arias L. 2008. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 134:124-146.
17. Singh K, Marchand B, Kirby KA, Michailidis E, Sarafianos SG. 2010. Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase. Viruses 2:606-638.
18. Arts EJ, Hazuda DJ. 2012. HIV-1 antiretroviral drug therapy. Cold Spring Harb. Perspect. Med. 2:a007161. doi:10.1101/cshperspect.a007161.
19. Kodama EI, Kohgo S, Kitano K, Machida H, Gatanaga H, Shigeta S, Matsuoka M, Ohrui H, Mitsuya H. 2001. 4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob. Agents Chemother. 45:1539-1546.
20. Michailidis E, Marchand B, Kodama EN, Singh K, Matsuoka M, Kirby KA, Ryan EM, Sawani AM, Nagy E, Ashida N, Mitsuya H, Parniak MA, Sarafianos SG. 2009. Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-ethynyl-2-fluoro- 2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J. Biol. Chem. 284:35681-35691.
21. Kawamoto A, Kodama E, Sarafianos SG, Sakagami Y, Kohgo S, Kitano K, Ashida N, Iwai Y, Hayakawa H, Nakata H, Mitsuya H, Arnold E, Matsuoka M. 2008. 2'-Deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int. J. Biochem. Cell Biol. 40:2410-2420.
22. Michailidis E, Ryan EM, Hachiya A, Kirby KA, Marchand B, Leslie MD, Huber AD, Ong YT, Jackson JC, Singh K, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG. 2013. Hypersusceptibility mechanism of tenofovir-resistant HIV to EFdA. Retrovirology 10:65. doi:10.1186/1742-4690-10-65.
23. Michailidis E, Singh K, Ryan EM, Hachiya A, Ong YT, Kirby KA, Marchand B, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG. 2012. Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant. Cell. Mol. Biol. 58:187-195.
24. Murphey-Corb M, Rajakumar P, Michael H, Nyaundi J, Didier PJ, Reeve AB, Mitsuya H, Sarafianos SG, Parniak MA. 2012. Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo. Antimicrob. Agents Chemother. 56:4707-4712.
25. Nakata H, Amano M, Koh Y, Kodama E, Yang G, Bailey CM, Kohgo S, Hayakawa H, Matsuoka M, Anderson KS, Cheng YC, Mitsuya H. 2007. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on humanDNApolymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Antimicrob. Agents Chemother. 51:2701-2708.
26. Sohl CD, Singh K, Kasiviswanathan R, Copeland WC, Mitsuya H, Sarafianos SG, Anderson KS. 2012. Mechanism of interaction of human mitochondrialDNApolymerase gamma with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity. Antimicrob. Agents Chemother. 56: 1630-1634.
27. Adams A, Harkness RA. 1976. Adenosine deaminase activity in thymus and other human tissues. Clin. Exp. Immunol. 26:647-649.
28. Johnson MA, Ahluwalia G, Connelly MC, Cooney DA, Broder S, Johns DG, Fridland A. 1988. Metabolic pathways for the activation of the antiretroviral agent 2', 3'-dideoxyadenosine in human lymphoid cells. J. Biol. Chem. 263:15354-15357.
29. Chilson OP, Fisher JR. 1963. Some comparative studies of calf and chicken adenosine deaminase. Arch. Biochem. Biophys. 102:77-85.
30. Baer HP, Drummond GI, Gillis J. 1968. Studies on the specificity and mechanism of action of adenosine deaminase. Arch. Biochem. Biophys. 123:172-178.
31. Simon LN, Bauer RJ, Tolman RL, Robins RK. 1970. Calf intestine adenosine deaminase. Substrate specificity. Biochemistry 9:573-577.
32. Maguire MH, Sim MK. 1971. Studies on adenosine deaminase. 2. Specificity and mechanism of action of bovine placental adenosine deaminase. Eur. J. Biochem. 23:22-29.
33. Agarwal RP, Sagar SM, Parks RE, Jr. 1975. Adenosine deaminase from human erythrocytes: purification and effects of adenosine analogs. Biochem. Pharmacol. 24:693-701.
34. Cooney DA, Ahluwalia G, Mitsuya H, Fridland A, Johnson M, Hao Z, Dalal M, Balzarini J, Broder S, Johns DG. 1987. Initial studies on the cellular pharmacology of 2', 3'-dideoxyadenosine, an inhibitor of HTLVIII infectivity. Biochem. Pharmacol. 36:1765-1768.
35. Yarchoan R, Mitsuya H, Thomas RV, Pluda JM, Hartman NR, Perno CF, Marczyk KS, Allain JP, Johns DG, Broder S. 1989. In vivo activity against HIV and favorable toxicity profile of 2', 3'-dideoxyinosine. Science 245:412-415.
36. Kirby KA, Singh K, Michailidis E, Marchand B, Kodama EN, Ashida N, Mitsuya H, Parniak MA, Sarafianos SG. 2011. The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase. Cell Mol. Biol. 57:40-46.
37. Marquez VE, Ezzitouni A, Russ P, Siddiqui MA, Ford H, Jr, Feldman RJ, Mitsuya H, George C, Barchi JJ, Jr. 1998. Lessons from the pseudorotational cycle: conformationally rigid AZT carbocyclic nucleosides and their interaction with reverse transcriptase. Nucleosides Nucleotides 17:1881-1884.
38. Marquez VE, Ezzitouni A, Russ P, Siddiqui MA, Ford H, Jr, Feldman RJ, Mitsuya H, George C, Barchi JJ, Jr. 1998. HIV-1 reverse transcriptase can discriminate between two conformationally locked carbocyclic AZT triphosphate analogues. J. Am. Chem. Soc. 120:2780-2789.
39. Mu L, Sarafianos SG, Nicklaus MC, Russ P, Siddiqui MA, Ford H, Jr, Mitsuya H, Le R, Kodama E, Meier C, Knispel T, Anderson L, Barchi JJ, Jr, Marquez VE. 2000. Interactions of conformationally biased north and south 2'-fluoro-2', 3'-dideoxynucleoside 5'-triphosphates with the active site of HIV-1 reverse transcriptase. Biochemistry 39: 11205-11215.
40. Boyer PL, Julias JG, Marquez VE, Hughes SH. 2005. Fixed conformation nucleoside analogs effectively inhibit excision-proficient HIV-1 reverse transcriptases. J. Mol. Biol. 345:441-450.
41. Van Roey P, Taylor EW, Chu CK, Schinazi RF. 1990. Correlation of molecular conformation and activity of reverse transcriptase inhibitors. Ann. N. Y. Acad. Sci. 616:29-40.
42. Wang J, Choudhury D, Chattopadhyaya J, Eriksson S. 1999. Stereoisomeric selectivity of human deoxyribonucleoside kinases. Biochemistry 38: 16993-16999.
43. Marquez VE, Russ P, Alonso R, Siddiqui MA, Shin KJ, George C, Nicklaus MC, Dai F, Ford H, Jr. 1999. Conformationally restricted nucleosides. The reaction of adenosine deaminase with substrates built on a bicyclo[3.1.0]hexane template. Nucleosides Nucleotides 18:521-530.
44. Marquez VE, Russ P, Alonso R, Siddiqui MA, Hernandez S, George C, Nicklaus MC, Dai F, Ford H, Jr. 1999. Synthesis of conformationally restricted carbocyclic nucleosides: the role of the O(4')-atom in the key hydration step of adenosine deaminase. Helv. Chim. Acta 82: 2119-2129.
45. Ford H, Jr, Dai F, Mu L, Siddiqui MA, Nicklaus MC, Anderson L, Marquez VE, Barchi JJ, Jr. 2000. Adenosine deaminase prefers a distinct sugar ring conformation for binding and catalysis: kinetic and structural studies. Biochemistry 39:2581-2592.
46. Marquez VE, Schroeder GK, Ludek OR, Siddiqui MA, Ezzitouni A, Wolfenden R. 2009. Contrasting behavior of conformationally locked carbocyclic nucleosides of adenosine and cytidine as substrates for deaminases. Nucleosides Nucleotides Nucleic Acids 28:614-632.
47. Shuto S, Obara T, Itoh H, Kosugi Y, Saito Y, Toriya M, Yaginuma S, Shigeta S, Matsuda A. 1994. New neplanocin analogues. IV. 2-Fluoroneplanocin A: an adenosine deaminase-resistant equivalent of neplanocin A. Chem. Pharm. Bull. (Tokyo) 42:1688-1690.
48. Obara T, Shuto S, Saito Y, Snoeck R, Andrei G, Balzarini J, De Clercq E, Matsuda A. 1996. New neplanocin analogues. 7. Synthesis and antiviral activity of 2-halo derivatives of neplanocin A. J. Med. Chem. 39:3847-3852.
49. Boyer PL, Julias JG, Ambrose Z, Siddiqui MA, Marquez VE, Hughes SH. 2007. The nucleoside analogs 4'C-methyl thymidine and 4'C-ethyl thymidine block DNA synthesis by wild-type HIV-1 RT and excision proficient NRTI resistant RT variants. J. Mol. Biol. 371:873-882.
50. Vu BC, Boyer PL, Siddiqui MA, Marquez VE, Hughes SH. 2011. 4'-C-methyl-2'-deoxyadenosine and 4'-C-ethyl-2'-deoxyadenosine inhibit HIV-1 replication. Antimicrob. Agents Chemother. 55:2379-2389.
51. de Leeuw FAAM, Altona C. 1983. Computer assisted pseudorotational analysis of 5-membered rings by means of 3J.HH coupling constants: program PSEUROT. J. Comp. Chem. 4:428-437.
52. Glendening ED, Badenhoop JK, Reed AE, Carpenter JE, Bohmann JA, Morales CM, Weinhold F. 2001. NBO 5.0 program. Theoretical Chemistry Institute, University of Wisconsin, Madison, WI.
53. Weinhold F, Landis CR. 2001. Introduction to Natural Bond Orbitals, NBO 5.0 program, and recent extensions of localized bonding concepts. Chem. Educ. Res. Pract. 2:91-104.
54. Paul MK, Grover V, Mukhopadhyay AK. 2005. Merits of HPLC-based method over spectrophotometric method for assessing the kinetics and inhibition of mammalian adenosine deaminase. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 822:146-153.
55. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
56. Altona C, Sundaralingam M. 1972. Conformational analysis of the sugar ring in nucleosides and nucleotides: a new description using the concept of pseudorotation. J. Am. Chem. Soc. 94:8205-8212.
57. Siddiqui MA, Hughes SH, Boyer PL, Mitsuya H, Van QN, George C, Sarafinanos SG, Marquez VE. 2004. A 4'-C-ethynyl-2', 3'-dideoxynucleoside analogue highlights the role of the 3'-OH in anti-HIV active 4'-C-ethynyl-2'-deoxy nucleosides. J. Med. Chem. 47:5041-5048.
58. Young DW, Tollin P, Wilson HR. 1969. The crystal and molecular structure of thymidine. Acta Crystallogr. B 25:1423-1432.
59. Weinhold F, Landis CR. 2012. Discovering chemistry with natural bond orbitals. John Wiley and Sons, Inc., Hoboken, NJ.
60. Kelly MA, Vestling MM, Murphy CM, Hua S, Sumpter T, Fenselau C. 1996. Primary structure of bovine adenosine deaminase. J. Pharm. Biomed. Anal. 14:1513-1519.
61. Wiginton DA, Adrian GS, Hutton JJ. 1984. Sequence of human adenosine deaminase cDNA including the coding region and a small intron. Nucleic Acids Res. 12:2439-2446.
62. Durham JP, Ives DH. 1970. Deoxycytidine kinase. II. Purification and general properties of the calf thymus enzyme. J. Biol. Chem. 245:2276-2284.
63. Krenitsky TA, Tuttle JV, Koszalka GW, Chen IS, Beacham LM, III, Rideout JL, Elion GB. 1976. Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J. Biol. Chem. 251:4055-4061.
64. Weissman SM, Smellie RM, Paul J. 1960. Studies on the biosynthesis of deoxyribonucleic acid by extracts of mammalian cells. IV. The phosphorylation of thymidine. Biochim. Biophys. Acta 45:101-110.
65. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet AM. 2010. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin. Pharmacokinet. 49:17-45.
66. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H. 1986. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 83:8333-8337.
67. Wolfenden R, Frick L. 1986. Mechanisms of enzyme action and inhibition: transition state analogues for acid-base catalysis. J. Protein Chem. 5:147-155.
68. Frick L, Wolfenden R, Smal E, Baker DC. 1986. Transition-state stabilization by adenosine deaminase: structural studies of its inhibitory complex with deoxycoformycin. Biochemistry 25:1616-1621.
69. Orozco M, Lluis C, Mallol J, Canela EI, Franco R. 1989. Theoretical approximation to the reaction mechanism of adenosine deaminase. Quant. Struct. Act. Relat. 8:109-114.
70. Orozco M, Canela EI, Franco R. 1990. Theoretical study of the hydroxyl nucleophilic attack on the 6-aminopyrimidine molecule: functional implications in the reaction mechanism of nucleoside deaminative enzymes. J. Org. Chem. 55:2630-2637.
71. Suydam IT, Strobel SA. 2008. Fluorine substituted adenosines as probes of nucleobase protonation in functional RNAs. J. Am. Chem. Soc. 130: 13639-13648.